摘要
Background:Human neutrophil peptide-1(HNP-1)is a commonly investigated therapeutic agent.However,its role in hypertensive left ventricular hypertrophy(HLVH)remains unclear.Methods:We measured HNP-1 levels in patients with hypertension and treated HLVH rat and H9c2 cell hypertrophy models with HNP-1.Cardiomyocyte hypertrophy indexes(i.e.,single-cell surface area,left ventricular fibrosis area,BNP levels,andβ-MHC levels)were measured with hematoxylin-eosin and Masson’s trichrome staining and WB.NF-κB signaling factors(i.e.,IKKβ,p-IKKβ,IκBα,p-IκBα,p65,and p-p65)were measured with WB and qPCR.Finally,inflammatory factors(i.e.,IL-6,IL-1α,and TNF-α)were measured with ELISA.Results:HNP-1 levels were lower in the exposure than the control groups(M(95%CI),48.83(45.64–52.26)vs.59.03(55.62–62.54),P=0.000).Diminished HNP-1 was associated with HLVH occurrence in patients.HLVH rat and H9c2 cell hypertrophy models revealed elevated cardiomyocyte hypertrophy indexes and NF-κB signaling and inflam-matory factors.However,each HNP-1 treatment group showed lower levels of the aforementioned indices than were observed in the model groups.Conclusion:Diminished HNP-1 is a risk factor for HLVH.HNP-1 treatment may reverse HLVH by inhibiting NF-κB signaling pathways.
基金
This study was supported by grants from the National Major Special Projects of China in 2019(1100310 and 2109901)
Guizhou Provincial Natural Science Foundation of China(gzwkj2023-268).
